Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Up 9.2% on Analyst Upgrade

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares rose 9.2% during mid-day trading on Wednesday after Wells Fargo & Company raised their price target on the stock from $1.00 to $3.00. Wells Fargo & Company currently has an equal weight rating on the stock. Ironwood Pharmaceuticals traded as high as $3.15 and last traded at $3.1550. Approximately 1,616,861 shares changed hands during mid-day trading, a decline of 37% from the average daily volume of 2,557,880 shares. The stock had previously closed at $2.89.

Other equities research analysts have also recently issued research reports about the stock. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.34.

Institutional Trading of Ironwood Pharmaceuticals

Large investors have recently modified their holdings of the company. Inspire Investing LLC raised its position in Ironwood Pharmaceuticals by 138.3% in the second quarter. Inspire Investing LLC now owns 552,420 shares of the biotechnology company’s stock worth $396,000 after acquiring an additional 320,595 shares during the period. Acadian Asset Management LLC increased its stake in shares of Ironwood Pharmaceuticals by 160.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,645,189 shares of the biotechnology company’s stock worth $3,878,000 after purchasing an additional 1,630,726 shares in the last quarter. Voleon Capital Management LP increased its stake in shares of Ironwood Pharmaceuticals by 952.4% in the 1st quarter. Voleon Capital Management LP now owns 870,629 shares of the biotechnology company’s stock worth $1,280,000 after purchasing an additional 787,901 shares in the last quarter. Focus Partners Advisor Solutions LLC raised its holdings in Ironwood Pharmaceuticals by 284.6% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 29,409 shares during the period. Finally, GSA Capital Partners LLP lifted its position in Ironwood Pharmaceuticals by 3,683.6% during the first quarter. GSA Capital Partners LLP now owns 524,676 shares of the biotechnology company’s stock valued at $771,000 after purchasing an additional 510,809 shares in the last quarter.

Ironwood Pharmaceuticals Stock Up 7.6%

The company has a fifty day simple moving average of $1.58 and a 200-day simple moving average of $1.08. The firm has a market cap of $505.17 million, a P/E ratio of -62.19 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.09 by $0.15. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The firm had revenue of $122.06 million for the quarter, compared to the consensus estimate of $74.22 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.